Featured

Status

Health Topics

Any Category
Chemicals and Drugs
Clear Filters

Search Clinical Trials

130 Results
Completed
The Efficacy of Doxazosin for Cocaine Users
The NE system, especially the alpha 1-adrenergic receptor, may play an important role in cocaine addiction in humans. The results of this study will provide medical safety data on the …
Baylor Role: Lead Sponsor
Completed
An ACE Inhibitor (Perindopril) or an Angiotensin Receptor Blocker (Candesartan) as a Treatment for Methamphetamine Dependence
Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to …
Baylor Role: Lead Sponsor
Completed
Investigation of Cycloserine as a Smoking Cessation Treatment
See brief summary
Baylor Role: Lead Sponsor
Active, Not Recruiting
Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT
The donor gave us blood to make CD19 chimeric receptor trivirus specific T cells in the laboratory. These cells were grown and frozen for the subject. To make these special …
Baylor Role: Lead Sponsor
Completed
Pain and Anxiety Management With Oral Narcotic for Pediatric Suture Repair
A prospective, double-blind, placebo-controlled, randomized clinical trial in a tertiary care pediatric emergency department with an annual census of 80,000 visits per year. Patients will be randomized by a randomization …
Baylor Role: Lead Sponsor
Completed
Rivastigmine and Huperzine A as Treatments for Cocaine Dependence
The purpose of this study is to evaluate the interactions between cocaine and oral rivastigmine and between cocaine and oral huperzine A (HupA). The following Specific Aims are proposed: 1. …
Baylor Role: Lead Sponsor
Completed
Optimization of IV Ketamine for Treatment Resistant Depression
Existing treatments for major depressive disorder (MDD) generally take weeks to months to exert their maximal benefit. There is an urgent need to develop rapid-acting treatments for MDD. Ketamine, a …
Baylor Role: Lead Sponsor
Completed
Syphilis Response to Higher Penicillin Dosage: The 2.4 Versus 7.2 Study
The investigators conducted a prospective, randomized, open label study at three clinical sites including Thomas Street Health Center and North West Clinic (Harris Health System), and the Michael E. DeBakey …
Baylor Role: Lead Sponsor
Withdrawn
Addition of Lactobacillus to Metronidazole in Treatment of CDAD
Clostridium difficile associated disease (CDAD), which nearly always follows antibiotic therapy, has become increasingly common and important in American hospitals, causing substantial morbidity and mortality. Metronidazole is the recommended treatment …
Baylor Role: Collaborator
Completed
Sequential and Hybrid Therapies for H Pylori Infection
The purpose of this study is to test whether the 14-day sequential therapy ( esomeprazole plus amoxicillin dual therapy for 7 days followed by triple therapy with esomeprazole, clarithromycin, and …
Baylor Role: Collaborator